<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01394055</url>
  </required_header>
  <id_info>
    <org_study_id>RM-131-003</org_study_id>
    <nct_id>NCT01394055</nct_id>
  </id_info>
  <brief_title>Study to Assess Pharmacodynamics of RM-131 in Patients With Diabetic Gastroparesis</brief_title>
  <official_title>Official Title: A Phase 1, Randomized, Double-blind, Placebo-controlled, Single Dose, 2-Period Crossover Study to Evaluate the Pharmacodynamics of RM-131 Administered to Patients With Diabetic Gastroparesis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Motus Therapeutics, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Motus Therapeutics, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the pharmacodynamic (PD) and pharmacokinetic (PK)&#xD;
      profile and the safety and tolerability of RM-131 in patients with diabetes mellitus and&#xD;
      delayed gastric emptying.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>July 2011</start_date>
  <completion_date type="Actual">December 2012</completion_date>
  <primary_completion_date type="Actual">November 2012</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pharmacodynamic (PD) effects of RM-131 on gastric emptying</measure>
    <time_frame>Day 1 at baseline vs Day 1 at 6 hours after dosing in Period 1 and Day 1 at baseline vs Day 1 at 6 hours after dosing in Period 2</time_frame>
    <description>Change from baseline in gastric half-emptying time by scintigraphy (solids and liquids)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety and tolerability of RM-131</measure>
    <time_frame>Day 1 and 2 after dosing in Period 1 and Day 1 and 2 after dosing in Period 2</time_frame>
    <description>Number of participants with adverse events</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics (PK) of RM-131</measure>
    <time_frame>Day 1 at baseline vs Day 1 at 6 hours after dosing in Period 1 and Day 1 at baseline vs Day 1 at 6 hours after dosing in Period 2</time_frame>
    <description>Median T-max of RM-131 levels in patients with type 2 diabetes mellitus</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">20</enrollment>
  <condition>Diabetes Mellitus Type 1 and 2</condition>
  <condition>Diabetes Mellitus Complications</condition>
  <condition>Gastroparesis</condition>
  <condition>Gastrointestinal Motility Disorder</condition>
  <arm_group>
    <arm_group_label>RM-131</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>RM-131</intervention_name>
    <description>100 μg subcutaneously once</description>
    <arm_group_label>RM-131</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Matching placebo volume subcutaneously once</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:&#xD;
&#xD;
          -  Able to provide written informed consent prior to any study procedures.&#xD;
&#xD;
          -  Diagnosis of Type 1 or 2 diabetic gastroparesis.&#xD;
&#xD;
          -  Controlled Type 1 or 2 diabetes mellitus (HbA1c &lt;10.1%).&#xD;
&#xD;
          -  Stable concomitant medications defined as no changes in regimen for at least 2 weeks&#xD;
             prior to Period 1 (daily adjustments of insulin doses are permitted).&#xD;
&#xD;
          -  Body mass index of 18-40 kg/m².&#xD;
&#xD;
        Key Exclusion Criteria:&#xD;
&#xD;
          -  Unable or unwilling to provide informed consent or to comply with study procedures.&#xD;
&#xD;
          -  History of gastric surgery such as fundoplication, gastrectomy, gastric pacemaker&#xD;
             placement, vagotomy, bariatric procedure. (Note: history of diagnostic endoscopy is&#xD;
             not exclusionary).&#xD;
&#xD;
          -  Acute or chronic illness or history of illness, which in the opinion of the&#xD;
             Investigator, could pose a threat or harm to the patient or obscure interpretation of&#xD;
             laboratory test results or interpretation of study data such as frequent angina, Class&#xD;
             III or IV congestive heart failure, poor renal or hepatic function, etc.&#xD;
&#xD;
          -  Any clinically significant abnormalities on screening laboratories as determined by&#xD;
             the Investigator.&#xD;
&#xD;
          -  Abnormal 12-lead electrocardiogram (ECG), including evidence of acute myocardial or&#xD;
             subendocardial ischemia and clinically significant arrhythmias or conduction&#xD;
             abnormalities or blood pressure at screening except minor deviations deemed to be of&#xD;
             no clinical significance by the Investigator.&#xD;
&#xD;
          -  Poor venous access or inability to tolerate venipuncture.&#xD;
&#xD;
          -  Acute GI illness within 48 hours of Period 1.&#xD;
&#xD;
          -  Positive pregnancy test.&#xD;
&#xD;
          -  Participation in a clinical study within the 30 days prior to dosing in the present&#xD;
             study.&#xD;
&#xD;
          -  Any other reason, which in the opinion of the Investigator, would confound proper&#xD;
             interpretation of the study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michael Camilleri, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mayo Clinic</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Mayo Clinic</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2016</verification_date>
  <study_first_submitted>July 8, 2011</study_first_submitted>
  <study_first_submitted_qc>July 12, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 14, 2011</study_first_posted>
  <last_update_submitted>September 21, 2016</last_update_submitted>
  <last_update_submitted_qc>September 21, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 22, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Diabetes Mellitus Type 1 and 2</keyword>
  <keyword>Delayed Gastric Emptying</keyword>
  <keyword>Gastroparesis</keyword>
  <keyword>Gastrointestinal Motility Disorder</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gastroparesis</mesh_term>
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 1</mesh_term>
    <mesh_term>Diabetes Complications</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

